Purchase Order 75N91022P00515
Award Date 5/27/22
Potential Completion Date 5/26/23
Potential Value $396K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of genomics sequencing systems and reagents, for the procurement of an Illumina NextSeq 550 sequencing system. The $266,475 award was made on May 24, 2019 with an August 22, 2019 completion date. This purchase will complement the NCI's existing Illumina NextSeq 500 and MiSeq instruments used by...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents, to provide an Illumina NextSeq 2000 genetic analysis sequencer. The sequencer will be used to acquire whole genome, whole exome, and whole transcriptome data to support the National Cancer Institute's efforts to develop novel cancer...
- This is a $202,000.00 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. for the provision of an Illumina NextSeq 500 sequencing system. The contract has no set-aside designation. Through past contract awards, Illumina has provided a range of genomic sequencing instruments, reagents, and support services to various federal agencies including the NIH, Centers for Disease Control and...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $238,017.50 firm fixed price purchase order to Illumina, Inc. for the acquisition of an Illumina NextSeq 2000 sequencing system. The award did not include any set-aside designation. The sequencing system will support the National Cancer Institute's Surgery Branch in developing novel immunotherapies for the treatment of various cancers, including melanoma, gastrointestinal, lung, and...
- Illumina, Inc. has been awarded a $124,564.88 firm fixed price delivery order by the Department of Health and Human Services' National Institutes of Health National Cancer Institute for reagents and consumables. As the sole manufacturer of the sequencing instruments utilized by the agency, Illumina will provide proprietary supplies to support genomic sequencing and analysis at the agency's San Diego, California facility. No set-aside designation was applied to this order issued under an existing...
- This federal contract award is for the purchase of (QTY 2) Illumina NextSeq 550Dx sequencers by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI). The total potential value of the firm fixed price purchase order is $630,846.00. The contract was awarded to the prime vendor Illumina, Inc., a manufacturer of genomic sequencing and analysis products. The sequencing systems are intended to support the NCI's clinical next-generation...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $55,138.80 firm fixed price delivery order contract to Illumina, Inc. of San Diego, California for biological reagents. As the sole manufacturer of the sequencing instruments used by the agency, Illumina will provide consumables and supplies to support genomic sequencing and analysis efforts at its place of performance in San Diego. No set-aside provision was applied to this award made...
- The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, has awarded a $19,240 firm fixed price delivery order contract to Illumina, Inc. of San Diego, California. The contract is for supplies to support the agency's biomedical research mission. Illumina will provide products under the contract through December 2023 to assist NCI in advancing its goals of understanding, detecting and treating cancer through research. No...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute awarded a $228,009.60 firm fixed-price delivery order contract to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The contract has a completion date of March 19, 2024 and is for the provision of biological kits. Illumina has a history of providing sequencing systems, consumables, and bioinformatics products to federal agencies like the NIH,...
- This is a Federal contract award to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions, to provide a NextSeq 500 Sequencing System. The $239,875.00 firm fixed price contract was awarded on September 6, 2016 by the National Cancer Institute, a component of the National Institutes of Health, with a completion date of December 31, 2016. The contract does not have a set-aside designation. Illumina has extensive experience providing sequencing instruments,...